

Electronic Acknowledgement Receipt

EFS ID:	9403070
Application Number:	10534348
International Application Number:	
Confirmation Number:	4929
Title of Invention:	Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
First Named Inventor/Applicant Name:	Karen Silence
Customer Number:	23628
Filer:	Erik J. Spek/Eileen Flaherty
Filer Authorized By:	Erik J. Spek
Attorney Docket Number:	A0848.70005US00
Receipt Date:	08-FEB-2011
Filing Date:	09-MAY-2005
Time Stamp:	19:15:23
Application Type:	U.S. National Stage under 35 USC 371

Payment information:

Submitted with Payment	no
------------------------	----

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	NPL Documents	Third_Party_Observations_data_06172009_Munich.pdf	138483 60ec0bbb9676174d2c908f8107271b7af02d95578	no	3

Warnings:

Information:

2	NPL Documents	Third_Party_Observations_dated_09012009_Barcelona.pdf	125817 f18262a894c0d175460485c1d6c46175c0b4665	no	4
Warnings:					
Information:					
3	NPL Documents	Third_Party_Observations_dated_09042009_Paris.pdf	246596 5403c1bde6072b3c95963a98b3c0d10405c0b3694	no	4
Warnings:					
Information:					
4	NPL Documents	Summary_of_telephone_consultation_submitted_09252009.pdf	26793 11763db078-457573bec75e0b0ee0ac1afddcc7c7c	no	1
Warnings:					
Information:					
5	NPL Documents	Letter_of_Opponent_re_Opp_Proc_dated_09252009.pdf	190208 4279d4184116c3d4978c7d6c4de78dd0e9d0f0af	no	4
Warnings:					
Information:					
6	NPL Documents	Letter_of_Opponent_re_Opp_Proc_dated_12102009.pdf	1749312 73dce95c9ba3dc78979ebc08f526dcff3bc72eaf	no	34
Warnings:					
Information:					
7	NPL Documents	Decision_Revoking_European_Patent_EP_1517921_dated_04082010.pdf	69724 75c6d8bec763d1aa360d470d038ca50743e0a1dc	no	4
Warnings:					
Information:					
8	NPL Documents	Annex_to_the_Decision_Revoking_Eur_Patent_04082010.pdf	426703 d932ba065d773c558071c0ae7db676d0931c74ff	no	10
Warnings:					
Information:					
9	NPL Documents	Annex_to_the_Decision_Revoking_Eur_Patent_Opposition_04082010.pdf	310856 7376c6d1d41006cc573737e6dc3d99a02219e05d61	no	8
Warnings:					
Information:					
10	NPL Documents	Annex_to_the_Decision_Revoking_Eur_Patent_Opposition_Grounds_for_Decision_to_Revok_e_04082010.pdf	1097502 770881e8dc420a79fd4070caae550501e040011	no	17
Warnings:					
Information:					

11	NPL Documents	Main_Request_filed_by_Patentee_07302010.pdf	104553 66ef8e05bfe1082af0d5c5a0b17a9141b8b	no	3
Warnings:					
Information:					
12	NPL Documents	Aux_Request1_filed_by_Patentee_07302010.pdf	112024 f7d2a7ab5219d51886d7f113e16c016c79378d	no	4
Warnings:					
Information:					
13	NPL Documents	Aux_Request2_filed_by_Patentee_07302010.pdf	130236 f5c1888eb4f1c243d3d8c10788783a0251384	no	4
Warnings:					
Information:					
14	NPL Documents	Aux_Request3_filed_by_Patentee_07302010.pdf	119187 401a1d40e1c5071bc1482887b15d8726dc27433	no	4
Warnings:					
Information:					
15	NPL Documents	Statement_of_grounds_of_appeal_filed_by_patentee_07302010.pdf	1334355 e5bde4bfe1a0bd15479b373c1d513d24e353b3	no	29
Warnings:					
Information:					
16	NPL Documents	Barrios_et_al_J_Mol_Recog_2004_v17_p332.pdf	655949 a1943bbbae9525ce91414a5cda8565e70bd9907	no	7
Warnings:					
Information:					
17	NPL Documents	Birkett_Ch_3_Pharmacokinetics_Made_Easy_1998_p16.pdf	9203432 11bc92cdc56441298413ca94edd240738743b71	no	11
Warnings:					
Information:					
18	NPL Documents	Cheong_et_al_BiochemBiophysResComm_1990_v173_p795.pdf	272541 9881e613a29a573e71c3bc562647a65d4280c2	no	6
Warnings:					
Information:					
19	NPL Documents	Baniyash_et_al_EurJImmunol_1984_v14_p799.pdf	15685363 9f5a8f96ced768813223813f81e8f3566710411b	no	9
Warnings:					
Information:					

20	NPL Documents	Chen_et_al_NuclAcidsRes_2002_v30_p412.pdf	474644 8895a1b4f0b2c4ffe896cc7904c2d72080f239	no	4
Warnings:					
Information:					
21	NPL Documents	Chuang_et_al_PharmaceutRes_2002_v19_p569.pdf	965941 09bb4cc78b1668f3b3dce899ca1074154bc1629	no	9
Warnings:					
Information:					
22	NPL Documents	Cochran_et_al_ImmunolMethods_2004_v287_p147.pdf	1608376 6af534da7f45dc11e898255a833d4dc12358e7b	no	12
Warnings:					
Information:					
23	NPL Documents	Connelly_InnPharmTechnol_2005_p42.pdf	532556 enc99427f8a30675ac17ac81a77968e5c0648f1	no	5
Warnings:					
Information:					
24	NPL Documents	Conrath_et_al_AntimicrobAgentsChemother_2001_v45_p2807.pdf	163966 5b9f9827d6c8f4dc59c363ba53d448ce336e3328a	no	6
Warnings:					
Information:					
25	NPL Documents	Crombet-Ramos_et_al_IntJCancer_2002_v101_p567.pdf	2229893 a3bdc719b46dc58194dc51b40591af05b61e578b	no	9
Warnings:					
Information:					
26	NPL Documents	Davies_et_al_FEB5_Letts_1994_v339_p285.pdf	9383520 b186ceac6c7da003a1f8b12ce2ef6f6e5e2a4ac5	no	6
Warnings:					
Information:					
27	NPL Documents	Dennis_et_al_JBiolChem_2002_v277_p35035.pdf	294320 bba3eb845c1a18827c44aa264ab1179ba51ec2e	no	9
Warnings:					
Information:					
28	NPL Documents	Desmyter_et_al_JBiolChem_2002_v277_p23645.pdf	468491 c8773272eac880919023e157fa7a3e4384589	no	6
Warnings:					
Information:					

29	NPL Documents	Dolk_et_al_Appl_Environ_Microbiol_2005_v71_p442.pdf	837292 1e05b0d64754bb35599ec0fcca1a40452ba2d2	no	9
Warnings:					
Information:					
30	NPL Documents	Drejer_et_al_Diabetes_1991_v40_p1488.pdf	720175 d88e4f5e02465d5d882a021289f6e6c31f6188	no	8
Warnings:					
Information:					
31	NPL Documents	Dubnovitsky_et_al_Biochem_2000_v65_p1011.pdf	111201 511e01972f17902ab001-005e25c-c7d69d461	no	8
Warnings:					
Information:					
32	NPL Documents	Fahrner_et_al_BiotechnolEngRev_2001_v18_p301.pdf	1311403 a091d419001047e75d86115b18fcd6245c03ca	no	30
Warnings:					
Information:					
33	NPL Documents	Frenken_JBiotechnol_2000_v78_p11.pdf	802510 3d242abc361c08b9fb1421dc0f57382d1032e4d2	no	11
Warnings:					
Information:					
34	NPL Documents	Hamilton-Wessler_et_al_Diabetologia_1999_v42_p1254.pdf	676308 c15239ee055d9d651a2a29c144141087e2b742	no	10
Warnings:					
Information:					
35	NPL Documents	Harmsen_et_al_VetMicrobiol_2005_v111_p89.pdf	740434 45d8ce147560ca385ac49131f9056a78ceee1a2	no	10
Warnings:					
Information:					
36	NPL Documents	Heitner_et_al_JImmunolMethods_2001_v248_p17.pdf	792566 ae63a826ba38c3415bb6ca4818e0f86a8367	no	14
Warnings:					
Information:					
37	NPL Documents	Hey_et_al_TrendsBiotechnol_2005_v23_p514.pdf	895951 88d0d6d79f73e22f7f99abc38fb384f563f86c	no	9
Warnings:					
Information:					

38	NPL Documents	Holliger_et_al_Nature_Biotech_1997_v15_p632.pdf	1520751 a26b6deca16d15a513ba7e281a1b3cfd651b6	no	5
Warnings:					
Information:					
39	NPL Documents	Holt_et_al_TrendsInBiotech_2003_v21_p484.pdf	938229 1b3a6a11e7e34e34e3d71a379d391d2a65c1033a3a3	no	8
Warnings:					
Information:					
40	NPL Documents	Hoogenboom_et_al_Nature_Biotech_1997_v15_p125.pdf	418328 8d2590e7c7f53b37209c77291a7f7bcbec103e2746	no	2
Warnings:					
Information:					
41	NPL Documents	Hulme_et_al_Proc_R_Soc_Med_1966_v59_p509.pdf	551823 9216083d9b285db1eacdb2c8701dd8c6c58d49d	no	4
Warnings:					
Information:					
42	NPL Documents	Janeway_et_al_Immunobiology_1997_3rd_ed_part2_p31.pdf	1360227 305d86d11d36a7d6d42b75e8b5d254791d621	no	14
Warnings:					
Information:					
43	NPL Documents	Janeway_et_al_Immunobiology_1997_219-220.pdf	306387 386e611f52057e03118d7a32d72a3d811c09409db	no	5
Warnings:					
Information:					
44	NPL Documents	Kang_et_al_EJCancer_v38_p149_PosterSessions.pdf	103226 d11313c95d239edf90abaf4dbce1e24a9088d637aa	no	1
Warnings:					
Information:					
45	NPL Documents	King_ApplicationsandEnginofMonoclonalAntibodies_1998_p40.pdf	2380490 822d62ad4b3164e09b6a0041380412aac185d7	no	13
Warnings:					
Information:					
46	NPL Documents	Kruger_et_al_ApplMicrobiolBiotechnol_2006_v72_p732.pdf	144110 ed11abdbffac1993707e1e1b0d4b8f5d579cc5e1c	no	6
Warnings:					
Information:					

47	NPL Documents	Lauwereys_et_al_EMBOJ_1998_v17_p3512.pdf	457436 85213a75cc2ca9534e79c95d198167d4d75d47	no	9
Warnings:					
Information:					
48	NPL Documents	MacEwan_et_al_BrJPharmacol_2002_v135_p855.pdf	1982342 e1967a2155db185d6d4f4d8025d8154e71ca3531	no	21
Warnings:					
Information:					
49	NPL Documents	Mamot_et_al_CancerRes_2003_v63_p3154.pdf	684848 24204eb3f1b11a6b065f96b47d6311c6b5eaddb	no	8
Warnings:					
Information:					
50	NPL Documents	Mauri_et_al_JExpMed_2003_v197_p489.pdf	1039098 b1ba6a5a5e88b7b4d09acdb555626170ca4f72be	no	13
Warnings:					
Information:					
51	NPL Documents	Morelli_et_al_CancerRes_1996_v56_p2082.pdf	881961 2d1d6812612993a77a4d22790b6a6ebc78008122	no	4
Warnings:					
Information:					
52	NPL Documents	Muyldermans_et_al_TrendsBiochemSci_2001_v26_p230.pdf	552949 14e3a262ec7124356d4d6b2306d578b5bfc6a4d	no	6
Warnings:					
Information:					
53	NPL Documents	Muyldermans_et_al_JMolReco gnit_1999_v12_p131.pdf	1095524 66d511287003017d1e211b62e42b48a3585d4dc	no	11
Warnings:					
Information:					
54	NPL Documents	Nilsson_et_al_ProteinExpandPurification_1997_v11_p1.pdf	1140820 04768bcd296aa202a0a8b1516b3a09c3a2d6b	no	16
Warnings:					
Information:					
55	NPL Documents	Nygren_et_al_Vaccines_1991_v91_p363.pdf	248615 3d5c4ebd682f6f5d6cd8b3c078ec577efda5ce	no	6
Warnings:					
Information:					

56	NPL Documents	Pant_et_al_InfectDis_2006_v1 94_p1580.pdf	1334383 09d61046127e8f7ee8265087eb6c5e5b1 d4b6b17	no	9
Warnings:					
Information:					
57	NPL Documents	Presta_et_al_ThrombHaemost 2001_v85_p379.pdf	1034603 e19ce8ac02a0d6d8027754174bce81ca016 8075	no	11
Warnings:					
Information:					
58	NPL Documents	Reilly_et_al_ClinPharmacokinet _1997_v32_p313.pdf	1481098 40611eb0f88ca7a376c14a3d78cd05c10a772 129	no	11
Warnings:					
Information:					
59	NPL Documents	Miyajima_et_al_IntArchAllergyl mmunol_2002_v128_p24.pdf	683029 779498d03695bacc13ca6224ee8c2b36af0 316e4	no	9
Warnings:					
Information:					
60	NPL Documents	Reeck_et_al_Cell_1987_v50_p 667.pdf	257181 18c1410a46289151c5864369d679310a48f bae8	no	1
Warnings:					
Information:					
Total Files Size (in bytes):			75606639		

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.